Atominex Capsule 25 Mg

Atominex is a branded atomoxetine product marketed in Türkiye; the active substance is atomoxetine hydrochloride, a potent and highly selective norepinephrine reuptake inhibitor without direct stimulant activity. It is used as part of a comprehensive ADHD treatment program that includes psychological, educational, and social interventions.

Qualitative and Quantitative Composition

Each hard capsule of Atominex 25 mg contains atomoxetine hydrochloride equivalent to 25 mg atomoxetine as the active ingredient. Inactive ingredients (excipients) are those typical of atomoxetine capsules (e.g. capsule shell components and fillers), as listed in the national product information.

Mechanism of Action and Pharmacodynamics

Atomoxetine is a selective inhibitor of the presynaptic norepinephrine transporter, increasing synaptic norepinephrine concentrations in the prefrontal cortex and other brain regions implicated in ADHD. It has minimal affinity for dopamine transporter in the striatum and does not act as a psychostimulant, which differentiates it pharmacodynamically from methylphenidate and amphetamine derivatives.

In clinical studies, atomoxetine improves core ADHD symptoms (inattention, hyperactivity, impulsivity) and functional outcomes, with onset of effect typically within 1–4 weeks and continued incremental benefit over several weeks. Cardiovascular pharmacodynamic effects include modest mean increases in heart rate and blood pressure, although a subset of patients demonstrate more pronounced and sustained elevations.

Pharmacokinetic Properties

Atomoxetine is rapidly and extensively absorbed after oral administration, with peak plasma concentrations typically attained within 1–2 hours in extensive metabolizers. Absolute bioavailability is approximately 63 % in extensive CYP2D6 metabolizers and up to 94 % in poor metabolizers because of reduced first‑pass metabolism. The apparent steady‑state volume of distribution is about 0.85 L/kg, indicating extensive tissue distribution.

Administration with food does not significantly alter the extent of absorption (AUC) but may reduce peak concentration and delay time to Cmax, which can improve gastrointestinal tolerability in some patients. Plasma protein binding is high, predominantly to albumin.

Metabolism and Elimination

Atomoxetine is primarily metabolized in the liver via cytochrome P450 2D6 (CYP2D6) to 4‑hydroxyatomoxetine, which is subsequently glucuronidated. Extensive metabolizers have an elimination half‑life of about 5 hours, whereas poor metabolizers exhibit approximately 10‑fold higher exposure (AUC), 5‑fold higher Cmax, and a prolonged half‑life of around 24 hours. The drug and its metabolites are largely excreted in urine, with minor fecal elimination.

In moderate to severe hepatic impairment (Child–Pugh B–C), atomoxetine exposure increases approximately 2‑ to 4‑fold, necessitating dose reduction. Severe renal impairment and end‑stage renal disease also lead to higher systemic exposure, although dosing can usually be managed through careful titration.​

Indications and Clinical Use

Atominex (atomoxetine) is indicated for the treatment of ADHD in children from 6 years of age, adolescents, and adults as part of a comprehensive treatment program. Treatment initiation should follow a thorough diagnostic assessment based on DSM or ICD criteria, with confirmation that symptoms cause clinically significant functional impairment across settings.

Pharmacological treatment is not required in all patients; the decision to initiate Atominex should be individualized, weighing symptom severity, comorbidities, and response to non‑pharmacological interventions. Long‑term therapy is not automatically indefinite, and the need for continuation should be periodically re‑evaluated, especially after the first year of symptom stabilization.

Posology and Method of Administration

Atomoxetine can be administered once daily in the morning, or as two divided doses (morning and late afternoon/early evening) if tolerability or efficacy requires split dosing. Capsules should be swallowed whole with water and must not be opened; direct contact with capsule contents should be avoided.

Example Titration Regimens (based on atomoxetine data)

• Children and adolescents ≤70 kg: start at approximately 0.5 mg/kg/day, increase after a minimum of 3–7 days to a target dose of about 1.2 mg/kg/day; doses above 1.8 mg/kg/day or 120 mg/day (whichever is less) have not been systematically evaluated.

• Adolescents and adults >70 kg: start at 40 mg/day, increase after at least 3 days to 80 mg/day; some patients may benefit from up‑titration to a maximum of 100 mg/day.

Atominex 25 mg capsules are typically used as part of a titration schema to reach the calculated mg/kg or fixed dose (e.g. as an intermediate dose step or in combination with other strengths). In CYP2D6 poor metabolizers or patients receiving strong CYP2D6 inhibitors (e.g. fluoxetine, paroxetine), lower starting doses and slower titration are recommended, with cautious upward adjustments only after several weeks if needed.

Illustrative Dose Construction Using Atominex Strengths

All numerical examples are illustrative and must be adapted to local product strengths, regulatory limits, and individual patient characteristics.

Contraindications

Atominex (atomoxetine) is contraindicated in the following situations:

• Hypersensitivity to atomoxetine hydrochloride or any excipient.

• Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI, due to risk of serious, sometimes fatal, reactions.

• Severe cardiovascular disorders where increases in blood pressure or heart rate could be clinically significant (e.g. severe hypertension, advanced structural cardiac disease).​

• Pheochromocytoma or history of pheochromocytoma.​

• Narrow‑angle glaucoma.​

Special Warnings and Precautions

Suicidal Ideation and Psychiatric Monitoring

Atomoxetine carries a boxed warning for increased risk of suicidal ideation in children and adolescents with ADHD; careful monitoring for mood changes, agitation, or suicidal thinking is required, particularly during initial months of therapy or dose adjustments. Families and caregivers should receive explicit counseling to observe and report emergent psychiatric symptoms.

Cardiovascular and Cerebrovascular Risk

Atomoxetine causes mean increases in heart rate and blood pressure; 8–12 % of children/adolescents and 6–10 % of adults develop more pronounced changes (e.g. ≥20 bpm heart rate or ≥15–20 mmHg blood pressure). Among those with such changes, 15–32 % show sustained or progressive elevation, potentially contributing to long‑term cardiovascular complications such as myocardial hypertrophy.​

Baseline cardiovascular evaluation (including history, physical examination, and, when indicated, ECG) should precede treatment, with regular monitoring thereafter. Caution is advised in patients with pre‑existing hypertension, tachycardia, structural heart disease, or cerebrovascular disorders.

Hepatic Effects

Rare but serious cases of liver injury, including severe hepatocellular damage, have been reported with atomoxetine, sometimes leading to markedly elevated transaminases and jaundice. Therapy should be discontinued if laboratory or clinical signs of liver dysfunction (e.g. pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained flu‑like symptoms) emerge.​

Growth, Appetite, and Weight

Atomoxetine is associated with decreased appetite, weight loss, and slower growth in some children and adolescents, particularly during the first months of therapy. Regular monitoring of height, weight, and appetite is recommended, with consideration of dose adjustment or treatment interruption if clinically significant growth suppression is observed.

Use with CYP2D6 Inhibitors and Genetic Polymorphism

Coadministration with potent CYP2D6 inhibitors (e.g. fluoxetine, paroxetine, quinidine) significantly increases atomoxetine exposure, approximating levels seen in poor metabolizers. Patients known or suspected to be CYP2D6 poor metabolizers or those receiving strong inhibitors should start at lower doses and titrate more slowly, with close monitoring for adverse events.

Drug–Drug and Drug–Disease Interactions

Atomoxetine should be used cautiously with medications that:

• Increase blood pressure or heart rate, including certain decongestants or beta‑agonists such as high‑dose systemic salbutamol.

• Affect QT interval or electrolytes, especially in patients with concomitant risk factors.

• Inhibit CYP2D6, leading to elevated atomoxetine levels (e.g. fluoxetine, paroxetine, terbinafine).

Some studies indicate that intravenous salbutamol in higher systemic doses combined with atomoxetine can produce greater increases in heart rate and blood pressure, particularly following initial co‑administration, though effects tend to attenuate over several hours. Atomoxetine is not a significant inducer or inhibitor of major CYP enzymes at therapeutic concentrations and thus has a relatively low potential for pharmacokinetic interactions beyond CYP2D6.

Adverse Reactions

The most frequently reported adverse reactions with atomoxetine include:

• Gastrointestinal: nausea, vomiting, abdominal pain, decreased appetite.

• Central nervous system: headache, somnolence, dizziness, insomnia.

• Psychiatric: irritability, mood swings, anxiety.

• Cardiovascular: mild increases in heart rate and blood pressure.

• General: fatigue, asthenia.

In Turkish post‑marketing sources, decreased appetite, insomnia, and elevations of liver enzymes are specifically highlighted as potential adverse effects of Atominex.

Serious and Clinically Important Adverse Reactions

Serious risks, though uncommon, include:

• Suicidal ideation and behavior, particularly in younger patients.

• Significant and sustained hypertension or tachycardia.

• Severe liver injury with jaundice and markedly elevated transaminases.

• Rare severe allergic reactions (e.g. angioedema, anaphylaxis).

• Priapism in male patients.

If serious cardiovascular, hepatic, or psychiatric adverse events occur, discontinuation and urgent medical evaluation are indicated.

Example Summary Table of Selected Adverse Reactions

Use in Special Populations

• Children <6 years: Safety and efficacy have not been established; Atominex is not recommended.

• Elderly: Limited data; use only after careful risk–benefit assessment and close monitoring of cardiovascular status.​

• Hepatic impairment: Reduce initial and target doses in moderate to severe impairment (Child–Pugh B–C).​

• Renal impairment: Increased exposure reported in end‑stage renal disease; consider caution and gradual titration.​

• Pregnancy and lactation: Human data are limited; atomoxetine should be used only if potential benefit justifies potential risk to the fetus or infant.

Overdose Management

Symptoms of atomoxetine overdose may include somnolence, gastrointestinal upset, tachycardia, hypertension, mydriasis, and behavioral changes; seizures and QT prolongation have been reported at high doses or in mixed overdoses. There is no specific antidote; management is supportive, with monitoring of cardiovascular and respiratory status, consideration of activated charcoal if early after ingestion, and treatment of complications as clinically indicated.​

Clinical Positioning and Conclusion

Atominex Capsule 25 mg, containing atomoxetine hydrochloride, is a non‑stimulant pharmacological option for ADHD with a well‑characterized pharmacokinetic and safety profile. Its selective norepinephrine reuptake inhibition offers an alternative for patients who do not tolerate or respond to stimulant therapy, or in whom stimulants are contraindicated, provided that clinicians rigorously monitor cardiovascular, hepatic, and psychiatric parameters throughout treatment.